Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that …

Biotechnology

US, Morrisville [HQ]

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Insiders

Form 3/4/5

Transactions

Download

Track non-derivative insider transactions.

i = Indirect d = Direct cs = Common Stock

Download

Reported Owner(s)	Position Now	Transaction Date	Type	Position Change	Extra
Davidson Michael H. Director	$2,881 d cs 10% Holder	08/08/24	P	2,500 x $0 = $0	Footnotes Form 4 - Filed at 08/08/24 #1 . On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock ("Shares") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99. #2 The aggregate number of shares of common stock previously reported as 608,645, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
Proehl Gerald T Director	$1,667 d cs 10% Holder	08/08/24	P	1,666 x $0 = $0	Footnotes Form 4 - Filed at 08/08/24 #1 On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock ("Shares") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99. #2 The aggregate number of shares of common stock previously reported as 1,495, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
RelevantBeneficialStockOwner object (67)	$424,347 d cs 10% Holder	09/21/22	G	1,909,585 x $0 = $0	Footnotes Form 4 - Filed at 09/23/22 #1 Represents a gift of Issuer's common stock to the Stuart Rich 2022 Irrevocable Trust. a Spousal Lifetime Access Trust (the "Trust"), for the benefit of Reporting Person's spouse and their children. #2 The Reporting Person is special asset advisor to the Trust. As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
RelevantBeneficialStockOwner object (67)	$1,909,585 i cs 10% Holder	09/21/22	G	1,909,585 x $0 = $0	Footnotes Form 4 - Filed at 09/23/22 #1 Represents a gift of Issuer's common stock to the Stuart Rich 2022 Irrevocable Trust. a Spousal Lifetime Access Trust (the "Trust"), for the benefit of Reporting Person's spouse and their children. #2 The Reporting Person is special asset advisor to the Trust. As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
RelevantBeneficialStockOwner object (68)	$3,637,871 d cs 10% Holder	08/11/22	G	567,871 x $0 = $0	Footnotes Form 4 - Filed at 08/12/22 #1 Issuer's shares held in a grantor retained annuity trust (the "GRAT") were distributed to the reporting person upon termination of the GRAT and in satisfaction of an annuity due to the reporting person. #2 The reporting person's wife, Dorothy Doogan, is the trustee of the GRAT.

Get PRO Today

With PRO you will unlock 11 more insider transactions for Tenax Therapeutics, Inc.

Start Free 7-Day Trial Subscribe to PRO

Statistics

Sample Size: 16 Transactions

Sale (S)

0.00%

Buy (P)

4,166

12.50%

87.50%

Other Ownership

87.50%

Other Ownership

Individuals

We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:

Individuals

We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture: